Camurus (CAMRF) announced that the U.S. Food and Drug Administration has accepted for review the company’s resubmission of the New Drug Application for Oclaiz, octreotide extended-release injection, for the treatment of patients with acromegaly. The FDA has assigned a Prescription Drug User Fee Act target action date of 10 June 2026.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAMRF:
- Camurus’ acromegaly drug Oclaiz gains FDA review date after resubmitted US filing
- Camurus Increases Share Capital After Employee Stock Option Exercise
- Camurus Increases Shares and Votes Following Employee Stock Option Exercise
- Camurus Announces Nomination Committee for AGM 2026
- Camurus AB Earnings Call: Growth Amid Challenges